Davis Vision, Prevent Blindness Ohio and Summa Hospital’s Ophthalmology Department have launched an ongoing community partnership to provide needy Akron-area children with free vision care services.
Author: The Medical News
Early diagnosis can delay or halt progression of macular degeneration
February is Age-related Macular Degeneration and Low Vision Awareness month, providing an opportunity to inform and educate the public on the leading cause of vision loss for adults over the age of 65. Today, over 15 million of these adults suffer from…
Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world’s most innovative companies
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Compa…
Iris Pharma announces validation of new EIU model of ocular inflammation
Iris Pharma, a world leader CRO specialized in ophthalmology, today announced the validation of the Endotoxin-Induced Uveitis model, a new model of ocular inflammation.
Inexpensive drug therapy shows promise in treating premature infants with childhood blindness
A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.
Allergan receives FDA approval for expanded use of LAP-BAND System in adults with obesity
Allergan, today announced the U.S. Food and Drug Administration approved the expanded use of the LAP-BAND System, Allergan’s gastric band, for adults with obesity who have failed more conservative weight reduction alternatives, such as diet and exercis…
Phase III RISE study of Lucentis for DME meets primary endpoint
Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication…
R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis
R-Tech Ueno is pleased to announce the initiation of a Phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.
ScinoPharm to be Clinical Data’s sole API supplier of vilazodone hydrochloride during Viibryd’s launch
ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochlor…
Synexus wins first contract to conduct ophthalmology studies
Synexus, the world’s largest company responsible for the recruitment and running of clinical trials, has won its first contract to conduct ophthalmology studies.
Researchers discover molecular mechanism implicated in geographic atrophy
A team of researchers, led by University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, has discovered a molecular mechanism implicated in geographic atrophy, the major cause of untreatable blindness in the industrialized world.
CVVS scientist receives top UK award for ground-breaking research on vascular stem cells, eye disease
One of Northern Ireland’s leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen’s University.
Queen’s scientist awarded Royal Society Wolfson Research Merit Award
One of Northern Ireland’s leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen’s University.
UM researchers find genetic cause of retinitis pigmentosa
Researchers led by geneticists at the University of Miami Miller School of Medicine have identified a new gene that causes retinitis pigmentosa, a form of blindness, ending one South Florida family’s nearly 20-year search for what caused three of their…
Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.
Positive top-line results from ILUVIEN Phase 3 trial in patients with DME
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readou…
MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults
Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.
Loyola inaugurates clinic exclusively to treat children with headaches
Fortunately, in most cases the causes of childhood headaches are usually no cause for alarm, Schnitzler said. Children can get headaches from stress, anxiety, inadequate sleep, vision problems, caffeine or food sensitivities. To help pinpoint the cause…
Crossed eyes in adults can also be corrected
Since she was a baby, Carleen Trautz’s left eye turned outward, rather than looking straight ahead, and it made her life miserable.
Promising results from TheraTears Nutrition pilot trial in dry eye patients
Advanced Vision Research, Inc. today announced the publication in the journal Cornea of promising results from a pilot trial of dry eye patients taking TheraTears® Nutrition. The study demonstrated a reduction in dry eye symptoms and an increase in te…